Stage III Cutaneous Melanoma AJCC v7 Active Not Recruiting Phase 2 Trials for Nivolumab (DB09035)
Indication | Status | Phase |
---|---|---|
DBCOND0091046 (Stage III Cutaneous Melanoma AJCC v7) | Active Not Recruiting | 2 |
clinicaltrials.gov Identifier | Title | Purpose | Drugs |
---|---|---|---|
NCT02910700 | Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma | Treatment |